MD/sp

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.

Petitioner

v.

HORIZON THERAPEUTICS, INC. Patent Owner

PETITION FOR INTER PARTES REVIEW OF U.S. PATENT NO. 8,404,215/AND U.S. PATENT NO. 8,642,012

This is the Deposition of NEAL SONDHEIMER, held at the Offices of VICTORY VERBATIM REPORTING SERVICES, Suite 900, 222 Bay Street, Ernst & Young Tower, Toronto-Dominion Centre, Toronto, Ontario, on the 10th day of March, 2016.

A P P E A R A N C E S:
DAVID H. SILVERSTEIN}
AZIZ BURGY }
Axinn, Veltrop & Harkrider
114 West 47th Street
New York, New York 10036
EMER SIMIC }
ROBERT GREEN}
Green Griffith
NBC Tower
455 N. Cityfront Plaza Dr.
Suite 3100

Chicago, Illinois 60611

ALSO PRESENT: Lauren Stevens --- for the Petitioner

--- for the Patent Owner

Owner Ex. 2012

N. Sondheimer - 2

INDEX OF PROCEEDINGS

PAGE NUMBER

NEAL SONDHEIMER, affirmed Examination by:	
Ms. Simic	3 - 188
Re-Examination by: Mr. Silverstein	188 - 233
INDEX OF EXHIBITS CERTIFICATION ERRATA	234 235 236



1	 upon convening at 9:00 a.m.
2	 upon commencing at 9:00 a.m.
3	
4	MR. WEINGOTT: Good morning. It is nine
5	o'clock on the 10th of March, 2016. We're
6	at the offices of Victory Verbatim. This
7	is the deposition of Neal Sondheimer in the
8	matter of Par Pharmaceutical v. Horizon
9	Therapeutics. The reporter today is
10	Matthew Dixon and the videographer is Aaron
11	Weingott. Could I please have the parties
12	introduce themselves and who they act for?
13	MS. SIMIC: Emer Simic from Green
14	Griffith & Borg-Breen and with me is my
15	colleague, Robert Green, also of Green
16	Griffith. We represent Horizon
17	Therapeutics Inc., and also with us today
18	is Lauren Stevens from Horizon Therapeutics
19	Inc.
20	MR. SILVERSTEIN: David Silverstein from
21	Axinn, Veltrop & Harkrider, representing
22	Par Pharmaceutical Inc. in this matter, and
23	with me is my colleague, Aziz Burgy, also
24	from the Axinn firm.
25	MR. DIXON: So I'm just going to



1	administer the oath, sir. Would you just
2	raise your right hand? Do you solemnly
3	affirm that the evidence you're about to
4	give today will the truth, the whole truth
5	and nothing but the truth?
6	MR. SONDHEIMER: I do.
7	MR. DIXON: Very good. Thank you.
8	
9	NEAL SONDHEIMER, affirmed
10	EXAMINATION BY MS. SIMIC:
11	
12	Q. Good morning, Dr. Sondheimer.
13	A. Good morning.
14	Q. So Dr. Sondheimer, you have
15	submitted an expert declaration in the inter partes
16	review concerning U.S. patent number 8,642,012. Is
17	that right?
18	A. That's correct.
19	Q. Okay. I will give you a copy of
20	your declaration. It has been marked pursuant to
21	the IPR, Exhibit 1002. So Dr. Sondheimer, in your
22	declaration, Exhibit 1002, at page 33 you state
23	that, "A person of ordinary" At paragraph 66:
24	"A person of ordinary skill in the art
25	would have recognized that the experiments



1	in Brusilow '91 by themselves were
2	insufficient to completely determine the
3	excretion rate of PAGN after a dose of PAA
4	and would have sought additional
5	information, such as that contained in
6	Shiple and Sherwin to identify the true
7	rate of conversion"
8	Correct?
9	A. That's correct. I will be calling
10	it Shiple.
11	Q. Sorry, how do you pronounce
12	A. Shiple.
13	Q. Shiple, okay, me too, then. So both
14	Sherwin and Shiple report on the conversion rate of
15	PAA to PAGN in healthy subjects, correct?
16	A. That's correct. They are normal
17	subjects.
18	Q. Okay, and so they're not reporting
19	on conversion of PAA to PAGN in UCD patients. Is
20	that right?
21	A. That's correct.
22	Q. Okay, and prior to August, 2008, a
23	POSA would not have expected the amount of
24	conversion of PAA to PAGN in healthy subjects to be
25	the same as that in a urea cycle disorder patient.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

